まとめ
シメチジンは,ウォルファリンなどの経口抗凝固剤を服用している患者のプロトロンビン時間 (PT) を著しく延長します. この薬物相互作用は,代謝の抑制による可能性が高いため,同時治療中に注意が必要です.
科学分野:
- 薬理学 薬理学とは
- 薬物相互作用 薬物相互作用
- クリニカル・メディシン 臨床医学
背景:
- 口服抗凝固剤 (ウォルファリンなど) は,血栓塞栓症の予防に不可欠です.
- シメチジンは,酸性逆流や潰瘍に対する一般的に使用される薬です.
- 潜在的な薬物相互作用は,患者の安全を確保するために徹底的な調査を必要とします.
研究 の 目的:
- シメチジンと経口抗凝固剤療法との相互作用を調査する.
- プロトロンビン時間 (PT) とワルファリンレベルに対するシメチジンの影響を定量化するために.
- この薬物相互作用の基礎となる薬理学的メカニズムを解明する.
主な方法:
- 口服抗凝固剤を服用している6人の患者と,健康なボランティア7人を対象に実施された研究.
- プロトロンビン時間 (PT) と血ウォルファリン濃度が測定されました.
- ワルファリンとアンチピリンのクリアランスは,シメチジンの存在で評価されました.
主要な成果:
- シメチジン添加は,患者でPTを平均12.6秒延長した.
- ボランティアでは,シメチジンはPTを19.4秒から22.9秒に増加させた.
- 血のワルファリン濃度は0.96から1.76マイクログラム/mlに上昇し,薬のクリアランスは低下した.
結論:
- シメチジンは,経口抗凝固剤の抗凝固効果を著しく強化する.
- この相互作用は,薬物の代謝をシメチジンによって抑制される可能性が高い.
- シメチジンと経口抗凝固剤を併用する際には注意が必要です.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


